Locate providers:   

Kybella gains FDA Approval for Double Chin Reduction


Once known as ATX-101, Kybella has been FDA Approved as a Submental Contouring Injectable Drug

Today the FDA approved the first injectable procedure for treating the double chin. The fat melting procedure similar to lipodissolve previously known as ATX-101 has been undergoing studies for years and has finally received FDA approval.

Kybella for Double Chin Fat Reduction
Kythera Biopharmaceuticals Inc. plans to start selling Kybella in the second half of 2015. Kybella isn't approved for injection into any other part of the body. The FDA said the most common side effects of the drug included swelling, bruising, pain, numbness, redness and hardness in the treatment area, while more serious side effects included trouble swallowing and nerve injury that can cause an uneven smile or muscle weakness.

According to FDA.gov, "Kybella is identical to the deoxycholic acid that is produced in the body. Deoxycholic acid produced in the body helps the body absorb fats. Kybella is a cytolytic drug, which when injected into tissue physically destroys the cell membrane. When properly injected into submental fat, the drug destroys fat cells; however, it can also destroy other types of cells, such as skin cells, if it is inadvertently injected into the skin."